Novo Nordisk pauses ad campaign for obesity drug Wegovy amid unprecedented demand
Novo Nordisk is hitting the brakes on a national advertising campaign for obesity drug Wegovy.
After launching a TV commercial regionally earlier this year, Novo told Endpoints News it’s now pausing the local ads and postponing national advertising plans in an effort to keep demand in check for the popular drug, also known by its non-proprietary name semaglutide.
“Given the current situation, to avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” a Novo Nordisk spokesperson said via email.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters